MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study

• DOI: 10.1371/journal.pone.0165236
• Publication Date: 2016-11-15T14:02:15Z
• Authors: Okyaz Eminaga; Wei Wei; Sarah J. Hawley; Heidi Auman; Lisa F. Newcomb; Jeff Simko; Antonio Hurtado-Coll; Dean A. Troyer; Peter R. Carroll; Martin E. Gleave; Daniel W. Lin; Peter S. Nelson; Ian M. Thompson; Lawrence D. True; Jesse K. McKenney; Ziding Feng; Ladan Fazli; James D. Brooks
• Keywords: MUC1

The uncertainties inherent in clinical measures of prostate cancer (CaP) aggressiveness endorse the investigation clinically validated tissue biomarkers. MUC1 expression has been previously reported to independently predict aggressive localized cancer. We used a large cohort validate whether protein levels measured by immunohistochemistry (IHC) cancer, recurrence and survival outcomes after radical prostatectomy independent pathological parameters.MUC1 IHC was performed on multi-institutional microarray (TMA) resource including 1,326 men with median follow-up 5 years. Associations parameters were tested Chi-square test Wilcoxon rank sum test. Relationships outcome assessed univariable multivariable Cox proportional hazard models Log-rank test.The presence significantly associated extracapsular extension higher Gleason score, but not seminal vesicle invasion, age, positive surgical margins or pre-operative serum PSA levels. In analyses, staining worse free (RFS) (HR: 1.24, CI 1.03-1.49, P = 0.02), although disease specific (DSS, P>0.5). On margins, extension, as well increasing score RFS, while not. Positive (DSS), weakly overall (OS).In our large, rigorously designed validation cohort, adverse features, it an predictor prostatectomy.